Association Between Patient Demographics and Smoldering Multiple Myeloma Progression to Multiple Myeloma: A SEER-Medicare Data Analysis.

IF 2.7 4区 医学 Q2 HEMATOLOGY
Poy Theprungsirikul, Rong Wang, Ishfaq Ahmad, Natalia Neparidze, Xiaomei Ma, Su-Hsin Chang, Shi-Yi Wang
{"title":"Association Between Patient Demographics and Smoldering Multiple Myeloma Progression to Multiple Myeloma: A SEER-Medicare Data Analysis.","authors":"Poy Theprungsirikul, Rong Wang, Ishfaq Ahmad, Natalia Neparidze, Xiaomei Ma, Su-Hsin Chang, Shi-Yi Wang","doi":"10.1016/j.clml.2025.06.016","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>While several risk stratification models for smoldering multiple myeloma (SMM) to symptomatic multiple myeloma (MM) progression have been developed, the association between patient demographics, such as race, gender, and age, and SMM progression is not well understood.</p><p><strong>Methods: </strong>Analyzing surveillance, epidemiology, and end results (SEER)-Medicare data, we applied a previously developed algorithm to identify patients with SMM diagnosed between 2007 and 2019. We used noncancer patients from the 5% random sample of Medicare beneficiaries as the controls. Cox proportional hazards models were applied to assess the association between race/gender/age and the development of hypercalcemia, renal failure, anemia and bone disease among SMM patients and the controls. We applied bootstrapping to calculate the estimates hazard ratios (aHRs) and 95% confidence intervals (CIs) of progression among SMM patients, adjusting for that of the noncancer controls.</p><p><strong>Results: </strong>Out of 1235 identified SMM patients (median age 75 years, White 76.7%), 856 (69.3%) of them progressed to symptomatic MM. Race (Black vs. White aHR = 0.82, 95% CI: 0.65-1.01) and gender (male vs. female aHR = 0.99, 95% CI: 0.86-1.13) were not significantly associated with SMM progression. Only age was negatively associated with SMM progression (75-79 years vs. 66-69 years aHR = 0.71, 95% CI: 0.58-0.87; 80-84 years vs. 66-69 years aHR = 0.59; 95% CI: 0.46-0.74; and ≥ 85 years vs. 66-69 years aHR = 0.59; 95% CI: 0.45-0.75).</p><p><strong>Conclusion: </strong>This analysis provided insight into important parameters for MM natural history modeling by demonstrating that only age, but not race and gender, is negatively associated with SMM progression.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lymphoma, Myeloma & Leukemia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.clml.2025.06.016","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: While several risk stratification models for smoldering multiple myeloma (SMM) to symptomatic multiple myeloma (MM) progression have been developed, the association between patient demographics, such as race, gender, and age, and SMM progression is not well understood.

Methods: Analyzing surveillance, epidemiology, and end results (SEER)-Medicare data, we applied a previously developed algorithm to identify patients with SMM diagnosed between 2007 and 2019. We used noncancer patients from the 5% random sample of Medicare beneficiaries as the controls. Cox proportional hazards models were applied to assess the association between race/gender/age and the development of hypercalcemia, renal failure, anemia and bone disease among SMM patients and the controls. We applied bootstrapping to calculate the estimates hazard ratios (aHRs) and 95% confidence intervals (CIs) of progression among SMM patients, adjusting for that of the noncancer controls.

Results: Out of 1235 identified SMM patients (median age 75 years, White 76.7%), 856 (69.3%) of them progressed to symptomatic MM. Race (Black vs. White aHR = 0.82, 95% CI: 0.65-1.01) and gender (male vs. female aHR = 0.99, 95% CI: 0.86-1.13) were not significantly associated with SMM progression. Only age was negatively associated with SMM progression (75-79 years vs. 66-69 years aHR = 0.71, 95% CI: 0.58-0.87; 80-84 years vs. 66-69 years aHR = 0.59; 95% CI: 0.46-0.74; and ≥ 85 years vs. 66-69 years aHR = 0.59; 95% CI: 0.45-0.75).

Conclusion: This analysis provided insight into important parameters for MM natural history modeling by demonstrating that only age, but not race and gender, is negatively associated with SMM progression.

患者人口统计学与阴燃性多发性骨髓瘤进展到多发性骨髓瘤之间的关系:一项SEER-Medicare数据分析。
背景:虽然已经建立了几种阴燃性多发性骨髓瘤(SMM)到症状性多发性骨髓瘤(MM)进展的风险分层模型,但患者人口统计学(如种族、性别和年龄)与SMM进展之间的关系尚不清楚。方法:分析监测、流行病学和最终结果(SEER)-Medicare数据,应用先前开发的算法识别2007年至2019年诊断为SMM的患者。我们使用5%的医疗保险受益人随机样本中的非癌症患者作为对照。应用Cox比例风险模型评估种族/性别/年龄与SMM患者和对照组中高钙血症、肾衰竭、贫血和骨病发生之间的关系。我们应用bootstrapping计算SMM患者进展的估计风险比(aHRs)和95%置信区间(CIs),并根据非癌症对照进行调整。结果:在1235例确诊的SMM患者(中位年龄75岁,白人76.7%)中,856例(69.3%)进展为症状性MM。种族(黑人对白人aHR = 0.82, 95% CI: 0.65-1.01)和性别(男性对女性aHR = 0.99, 95% CI: 0.86-1.13)与SMM进展无显著相关。只有年龄与SMM进展呈负相关(75-79岁vs. 66-69岁aHR = 0.71, 95% CI: 0.58-0.87;80-84岁vs. 66-69岁aHR = 0.59;95% ci: 0.46-0.74;≥85岁vs. 66 ~ 69岁aHR = 0.59;95% ci: 0.45-0.75)。结论:该分析为MM自然历史建模提供了重要参数,表明只有年龄,而不是种族和性别,与SMM进展负相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.70
自引率
3.70%
发文量
1606
审稿时长
26 days
期刊介绍: Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信